<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The oncogenic human <z:e sem="disease" ids="C0019340" disease_type="Disease or Syndrome" abbrv="">herpes</z:e> virus, the Epstein-Barr virus (EBV), expresses EBNA1 in almost <z:hpo ids='HP_0000001'>all</z:hpo> forms of <z:mp ids='MP_0001799'>viral</z:mp> latency </plain></SENT>
<SENT sid="1" pm="."><plain>EBNA1 plays a major role in the maintenance of the <z:mp ids='MP_0001799'>viral</z:mp> genome and in the transactivation of <z:mp ids='MP_0001799'>viral</z:mp> transforming genes, including EBNA2 and latent membrane protein (LMP-1) </plain></SENT>
<SENT sid="2" pm="."><plain>However, it is unknown whether inhibition of EBNA1 from the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> disrupts the establishment of EBV's latency and transactivation of the <z:mp ids='MP_0001799'>viral</z:mp> oncogenes </plain></SENT>
<SENT sid="3" pm="."><plain>To address this, we measured <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> kinetics in the B cell lines <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">BALL</z:e>-1 and BJAB, which stably express a dominant-negative EBNA1 (dnE1) fused to green fluorescent protein (GFP) </plain></SENT>
<SENT sid="4" pm="."><plain>The EBV genome was surprisingly unstable 1 week post-<z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>: the average loss rate of EBV DNA from GFP- and GFP-dnE1-expressing cells was 53.4% and 41.0% per cell generation, respectively, which was substantially higher than that of an 'established'oriP replicon (2-4%) </plain></SENT>
<SENT sid="5" pm="."><plain>GFP-dnE1 did not accelerate loss of the EBV genome, suggesting that EBNA1-dependent licensing of the EBV genome occurs infrequently during the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In the <z:hpo ids='HP_0011011'>subacute</z:hpo> phase, establishment of EBV latency was completely blocked in GFP-dnE1-expressing cells </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, C/W promoter-driven transcription was strongly restricted in GFP-dnE1-expressing cells at 2 days post-<z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>These data suggest that inhibition of EBNA1 from the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> is effective in blocking the positive feedback loop in the transactivation of <z:mp ids='MP_0001799'>viral</z:mp> transforming genes, and in eradicating the EBV genome during the <z:hpo ids='HP_0011011'>subacute</z:hpo> phase </plain></SENT>
<SENT sid="9" pm="."><plain>Our results suggest that gene transduction of GFP-dnE1 could be a promising therapeutic and prophylactic approach toward EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>